Patents Assigned to AGENDIA N.V.
  • TREATMENT OF HER2 NEGATIVE, MAMMAPRINT HIGH RISK 2 BREAST CANCER
    Publication number: 20230330223
    Abstract: The invention relates to a PARP inhibitor, an immune checkpoint inhibitor, or a combination thereof, for use as a medicament. The invention further relates to a kit of parts and to a pharmaceutical composition comprising a PARP inhibitor and an immune checkpoint inhibitor, preferably for use in a method of treating a breast cancer.
    Type: Application
    Filed: April 26, 2021
    Publication date: October 19, 2023
    Applicant: Agendia N.V.
    Inventor: Annuska Maria GLAS
  • Means and methods for molecular classification of breast cancer
    Patent number: 10072301
    Abstract: The invention relates to a method of typing a sample from a breast cancer patient. More specifically, the invention relates to a method for classification of breast cancer according to the presence or absence of Estrogen Receptor (ER), Progesterone Receptor (PR) and Human Epidermal growth factor Receptor 2 (ERBB2; HER2). More specifically, the invention provides methods and means to classify breast cancer as ER positive, triple negative (ER?, PR? and HER2?) and HER2+.
    Type: Grant
    Filed: October 28, 2015
    Date of Patent: September 11, 2018
    Assignee: Agendia N.V.
    Inventors: Oscar Krijgsman, Paul Roepman, Annuska Maria Glas
  • Methods and means for molecular classification of colorectal cancers
    Patent number: 10036070
    Abstract: The invention relates to methods of typing a sample from a colorectal cancer patient based on the levels of RNA expression products in a cancer cell of the patient. The invention further relates to methods for determining a strategy for treatment of a patient suffering from colorectal cancer, and to methods for assigning treatment to a patient suffering from colorectal cancer.
    Type: Grant
    Filed: December 23, 2011
    Date of Patent: July 31, 2018
    Assignee: AGENDIA N.V.
    Inventors: Paul Roepman, Iris Simon, Tian Sun
  • Method and Means for Typing a Sample Comprising Cancer Cells Based on Oncogenic Signal Transduction Pathways
    Publication number: 20170292162
    Abstract: The invention is related to a method of determining whether an individual suffering from cancer is likely to respond to anti-EGFR and/or EGFR pathway therapy. In one aspect, the invention utilizes the expression level of a set of genes for determining said response. In a further aspect, the invention relates to a method of assigning treatment to an individual suffering from cancer.
    Type: Application
    Filed: April 19, 2017
    Publication date: October 12, 2017
    Applicant: Agendia N.V.
    Inventors: Tian Sun, Paul Roepman, Annuska Maria Glas, Rene Bernards, Iris Simon
  • Means and methods for molecular classification of breast cancer
    Patent number: 9175351
    Abstract: The invention relates to a method of typing a sample from a breast cancer patient. More specifically, the invention relates to a method for classification of breast cancer according to the presence or absence of Estrogen Receptor (ER), Progesterone Receptor (PR) and Human Epidermal growth facto Receptor 2 (ERBB2; HER2). More specifically, the invention Provides methods and means to classify breast cancer as ER positive, triple negative (ER?, PR? and HER2?) and HER2+.
    Type: Grant
    Filed: July 11, 2012
    Date of Patent: November 3, 2015
    Assignee: AGENDIA N.V.
    Inventors: Oscar Krijgsman, Paul Roepman, Annuska Maria Glas
  • Methods and Means for Typing a Sample Comprising Cancer Cells Based on Oncogenic Signal Transduction Pathways
    Publication number: 20130302321
    Abstract: The invention is related to a method of determining whether an individual suffering from cancer is likely to respond to anti-EGFR and/or EGFR pathway therapy. In one aspect, the invention utilizes the expression level of a set of genes for determining said response. In a further aspect, the invention relates to a method of assigning treatment to an individual suffering from cancer.
    Type: Application
    Filed: September 28, 2011
    Publication date: November 14, 2013
    Applicant: AGENDIA N.V.
    Inventors: Tian Sun, Paul Roepman, Annuska Maria Glas, Rene Bernards, Iris Simon